UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 
(Amendment No. 1)
*

 

GENEREX BIOTECHNOLOGY CORPORATION

(Name of Issuer)

 

Common stock, par value $.001

(Title of Class of Securities)

 

371485103

(CUSIP Number)

 

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨  Rule 13d-1(b)

 

x Rule 13d-1(c)

 

¨  Rule 13d-l(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

  Page 1 of 4 pages  

 

 

CUSIP No. 371485103 AMENDMENT NO. 1 to SCHEDULE 13G

 

 

 

1.  Names of Reporting Persons.

 

Creek Mountain Partners, Inc.

 

 

 

2.  Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)       

 

(b)       

 

 

 

3.  SEC Use Only

 

 

 

4.  Citizenship or Place of Organization

 

Delaware

 

 

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5.  Sole Voting Power
 
796,447 shares of common stock, par value $.001
 
6.  Shared Voting Power
 

 

7.  Sole Dispositive Power

 

796,447 shares of common stock, par value $.001

 

 

8.  Shared Dispositive Power

 

 

  

9.  Aggregate Amount Beneficially Owned by Each Reporting Person

 

796,447 shares of common stock, par value $.001

 

 

 

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

 

 

11.  Percent of Class Represented by Amount in Row (9)

 

1.66%

 

 

 

12.  Type of Reporting Person (See Instructions)

 

CO

 

 

 

  Page 2 of 4 pages  

 

 

CUSIP No. 371485103 AMENDMENT NO. 1 to SCHEDULE 13G

 

Item 1.

 

(a) Name of Issuer

 

GENEREX BIOTECHNOLOGY CORPORATION

 

(b) Address of Issuer’s Principal Executive Offices

 

10102 USA Today Way, Miramar, Florida 33025

 

Item 2.

 

(a) Name of Person Filing

 

Creek Mountain Partners, Inc.

 

(b) Address of Principal Business Office or, if none, Residence

 

PO Box 1445

Exmore, Virginia 23350

 

(c) Citizenship

 

Delaware

 

(d) Title of Class of Securities

 

Common stock, par value $.001

 

(e) CUSIP Number

 

371485103

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

 

(e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

(f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

(g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

(h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j) ¨ Group, in accordance with §240.13d- I (b)(1)(ii)(J).

 

Item 4. Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a) Amount beneficially owned: 796,447.

 

(b) Percent of class: 1.66% *

 

(c) Number of shares as to which the person has:

 

(i) Sole power to vote or to direct the vote: 796,447.

 

(ii) Shared power to vote or to direct the vote: _______.

 

(iii) Sole power to dispose or to direct the disposition of: 796,447.

 

  Page 3 of 4 pages  

 

 

(iv) Shared power to dispose or to direct the disposition of: _______.

 

* The percentage of the outstanding common stock of the Issuer reported in this Item 4 is based on the assumption that there were 47,859,074 shares of common stock of the Issuer outstanding as of December 31, 2019.

 

Item 5. Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

N/A

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

 

N/A

 

Item 8. Identification and Classification of Members of the Group

 

N/A

 

Item 9. Notice of Dissolution of Group

 

N/A

 

Item 10. Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date:       February 11, 2020 CREEK MOUNTAIN PARTNERS, INC.  
       
  By: /s/ RONALD F. MATTHEWS, JR.  

       
  Name: Ronald F. Matthews, Jr.  
  Title: President  

 

  Page 4 of 4 pages  

Generex Biotechnology (QB) (USOTC:GNBT)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Generex Biotechnology (QB) Charts.
Generex Biotechnology (QB) (USOTC:GNBT)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Generex Biotechnology (QB) Charts.